Physician profile
Matthew Meredith
NPI 1841811320
$2,621.69
in general payments reported to CMS, 2019-2025
21 companies · $638 in 2025
The $638 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $593 · 2024: $1,391 · 2025: $638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,621.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $539.49 | 2023-2025 | Rocklatan, Hydrus Microstent, Rhopressa |
| Abbvie INC. | $457.61 | 2023-2025 | |
| Bausch & Lomb Americas INC. | $292.12 | 2023-2024 | Xiidra, Miebo, Infuse |
| Glaukos Corporation | $147.09 | 2025 | Idosetr |
| Johnson & Johnson Surgical Vision, INC. | $147.00 | 2024 | Tecnis Iol |
| Sun Pharmaceutical Industries INC. | $134.86 | 2023-2025 | Cequa |
| Lkc Technologies, INC. | $123.43 | 2024 | |
| Dompe US, INC. | $111.80 | 2024-2025 | Oxervate |
| Regeneron Healthcare Solutions, INC. | $100.59 | 2024-2025 | Eylea Hd, Eylea |
| Amgen INC. | $83.05 | 2024-2025 | Tepezza |
| Oyster Point Pharma, INC. | $75.80 | 2024-2025 | Tyrvaya |
| Apellis Pharmaceuticals, INC. | $68.07 | 2023-2024 | Syfovre |
| Novartis Pharmaceuticals Corporation | $66.90 | 2023 | |
| Tarsus Pharmaceuticals, INC. | $61.77 | 2024-2025 | Xdemvy |
| Ani Pharmaceuticals, INC. | $47.87 | 2023-2025 | Purified Cortrophin Gel |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $39.85 | 2023-2024 | Vabysmo |
| Harrow Eye, LLC | $38.51 | 2024-2025 | Vevye |
| Mallinckrodt Hospital Products INC. | $36.09 | 2024 | Acthar |
| Alimera Sciences, INC. | $20.06 | 2024 | Yutiq, Iluvien |
| Horizon Therapeutics Plc | $15.45 | 2023 | Tepezza |
| Sight Sciences, INC. | $14.28 | 2024 | Omni Surgical System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Meredith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.